263 related articles for article (PubMed ID: 26055217)
1. Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.
Ueno H; Tsuchimochi W; Wang HW; Yamashita E; Tsubouchi C; Nagamine K; Sakoda H; Nakazato M
Diabetes Ther; 2015 Jun; 6(2):187-96. PubMed ID: 26055217
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
3. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
4. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Aoki K; Masuda K; Miyazaki T; Togashi Y; Terauchi Y
Endocr J; 2010; 57(8):667-72. PubMed ID: 20519806
[TBL] [Abstract][Full Text] [Related]
5. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
6. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
7. Single-dose acarbose decreased glucose-dependent insulinotropic peptide and glucagon levels in Chinese patients with newly diagnosed type 2 diabetes mellitus after a mixed meal.
Chen Z; Fu X; Kuang J; Chen J; Chen H; Pei J; Yang H
BMC Endocr Disord; 2016 Sep; 16(1):55. PubMed ID: 27686734
[TBL] [Abstract][Full Text] [Related]
8. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones.
Aoki K; Sato H; Terauchi Y
Endocr J; 2019 May; 66(5):395-401. PubMed ID: 31019154
[TBL] [Abstract][Full Text] [Related]
10. Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.
Kishimoto M; Noda M
Diabetes Ther; 2012 Nov; 3(1):11. PubMed ID: 23055336
[TBL] [Abstract][Full Text] [Related]
11. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
[TBL] [Abstract][Full Text] [Related]
12. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
13. Effect of Acarbose, Sitagliptin and combination therapy on blood glucose, insulin, and incretin hormone concentrations in experimentally induced postprandial hyperglycemia of healthy cats.
Mori A; Ueda K; Lee P; Oda H; Ishioka K; Arai T; Sako T
Res Vet Sci; 2016 Jun; 106():131-4. PubMed ID: 27234550
[TBL] [Abstract][Full Text] [Related]
14. Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study.
Sato M; Fujita H; Yokoyama H; Mikada A; Horikawa Y; Takahashi Y; Yamada Y; Waki H; Narita T
J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176545
[TBL] [Abstract][Full Text] [Related]
15. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
16. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
17. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels.
Aoki K; Kamiyama H; Masuda K; Kamiko K; Noguchi Y; Tajima K; Terauchi Y
Endocr J; 2014; 61(3):249-56. PubMed ID: 24389993
[TBL] [Abstract][Full Text] [Related]
18. Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance.
Masuda K; Aoki K; Terauchi Y
J Diabetes Investig; 2011 Nov; 2(6):435-40. PubMed ID: 24843527
[TBL] [Abstract][Full Text] [Related]
19. Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.
Okada K; Yagyu H; Kotani K; Yamazaki H; Ozaki K; Takahashi M; Nagashima S; Osuga J; Ishibashi S
Endocr J; 2013; 60(7):913-22. PubMed ID: 23574730
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment.
Horikawa Y; Enya M; Iizuka K; Chen GY; Kawachi S; Suwa T; Takeda J
J Diabetes Investig; 2011 Jun; 2(3):200-3. PubMed ID: 24843484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
